A pilot study of Galectin-3 targeting in chronic kidney fibrosis and kidney function decline

Aihua Qin, Wanling Zhou, Zhen Zhang, Qiuyuan Zhou, Jing Wang, Zhenfa Wang, Ziheng Zhou, Qihao Sun, Lianjiu Su, Zhiyong Peng · 2026

Read A pilot study of Galectin-3 targeting in chronic kidney fibrosis and kidney function decline by Aihua Qin, Wanling Zhou, Zhen Zhang, Qiuyuan Zhou, Jing Wang, Zhenfa Wang, Ziheng Zhou, Qihao Sun, Lianjiu Su, Zhiyong Peng (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13504992.txt.

Description

Aihua Qin leads a team testing whether blocking a sugar-binding protein can slow kidney scarring, in a 2026 pilot study. The protein, galectin-3, helps drive swelling and scar growth in chronic kidney disease. Its exact role and value as a drug target stayed partly open.

In human kidney samples the protein ran high and tracked with worse kidney function. In two mouse models of kidney injury, the protein rose in damaged tube cells. Mice lacking the gene scarred far less and kept better kidney blood values. Gene reads showed a key swelling pathway switched down. A drug that blocks the protein gave like gains in mice. The authors propose the protein as a treatment target, pending clinical proof.

Catalog record

CREATORAihua Qin, Wanling Zhou, Zhen Zhang, Qiuyuan Zhou, Jing Wang, Zhenfa Wang, Ziheng Zhou, Qihao Sun, Lianjiu Su, Zhiyong Peng
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE50969
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13504992

Browse the full library · About the Tower of Babel